F&G Annuities & Life, Inc. announced a 4% increase in its quarterly cash dividend to $0.26 per common share, up from $0.25. This dividend will be paid on December 31, 2026, to shareholders recorded by December 17, 2026. Additionally, the company declared a quarterly dividend of $0.859375 per share on its 6.875% Series A Mandatory Convertible Preferred Stock, payable January 15, 2027. This move reflects F&G's commitment to returning value to shareholders while continuing its focus on insurance solutions for retail and institutional clients.
F&G Annuities & Life's announcement of a 4% dividend increase provides context for readers. For those following the Financials sector, here is Pluang's market snapshot as of Nov 06, 2026 19:11 WIB: Among 142 priced US Financials stocks, 54 rose and 81 fell. Notable movers include HUT at USD 50.75 with a 10.45% gain and 58% buy order activity, GLXY at USD 14.16 up 9.09% with 100% buy orders, and WULF at USD 10.84 rising 7.54% despite 76% sell orders.
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...
The Indonesia data center market is projected to grow from USD 2.08 billion in 2027 to USD 4.05 billion by 2032, at a CAGR of 14.28%. Growth is fueled by expanding hyperscaler cloud infrastructure, rising digital workloads, increasing demand for colo...
The S&P 500 Dividend Aristocrats, a group of 68 companies that have increased their dividends for at least 25 consecutive years, have recently outperformed the broader market. These stocks are favored by investors seeking steady and reliable dividend...
Emergent BioSolutions lowered its FY26 revenue and EBITDA guidance due to delays in government purchases and ongoing pricing pressure in the U.S. naloxone market. The company reported a sharp decline in gross margin and profitability, with adjusted E...
